Both everolimus and sirolimus are mTOR inhibitors employed as the primary modality for the management of TSC-associated renal angiomyolipomas (AMLs) and subependymal ependymal giant cell astrocytomas (SEGAs) in the CNS (Ebrahimi-Fakhari and Franz, 2020; Luo et al., 2021). The gene discussed is MTOR; the disease is tuberous sclerosis.